Biotinylated Human IL-5 Protein, His,Avitag™ (MALS verified)
分子别名（Synonym）
IL-5, TRF, IL5, Interleukin-5
表达区间及表达系统（Source）
Biotinylated Human IL-5, His,Avitag (IL5-H82Q5) is expressed from human 293 cells (HEK293). It contains AA Ile 20 - Ser 134 (Accession # P05113-1).
Predicted N-terminus: His
蛋白结构（Molecular Characterization）
This protein carries a polyhistidine tag at the N-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 16.7 kDa. The protein migrates as 20-25 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
The protein is designed as a dimer.
标记（Labeling）
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白标记度（Protein Ratio）
Passed as determined by the HABA assay / binding ELISA.
纯度（Purity）
>90% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景介绍
白细胞介素5（IL-5）是一种由2型辅助T细胞和肥大细胞产生的白细胞介素。这种由115个氨基酸（人类；小鼠为133个氨基酸）组成的TH2细胞因子属于造血因子家族。不同于该细胞因子家族的其他成员（即白细胞介素3和GM-CSF），这种糖蛋白的活性形式为同源二聚体。长期以来，白细胞介素5被视为过敏性鼻炎与哮喘等过敏疾病的致病因素，在这些疾病中可观察到循环系统、气道组织及诱导痰中的嗜酸性粒细胞数量显著增加。鉴于嗜酸性粒细胞与过敏性疾病（特别是过敏性哮喘）病理机制的高度关联性，学界普遍推测该类细胞在该疾病病理过程中起重要作用。靶向IL-5的药物包括美泊利单抗与瑞利珠单抗。
关键字： IL-5;IL-5蛋白;IL-5重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。